AI Insight
Chronic kidney disease currently affects approximately 800 million adults globally and is expected to rank as the fifth leading cause of death worldwide by 2040. Detection methods have advanced through improved glomerular filtration rate estimation using cystatin C, recognition of albuminuria as a critical screening marker, enhanced kidney biopsy techniques for better diagnostic accuracy, and emerging multiomics approaches that are deepening understanding of disease mechanisms. However, global disease burden assessment remains constrained by testing limitations and ascertainment bias, especially in low-income and middle-income countries.
Why it matters
Earlier and more accurate detection of chronic kidney disease through these advances could enable timely intervention to slow disease progression and reduce mortality rates. The development of precision medicine approaches through multiomics may eventually allow for personalized treatment strategies tailored to individual disease mechanisms.
Chronic kidney disease affects 788–844 million adults worldwide and is projected to become the fifth leading cause of death by 2040. Global burden estimates remain limited by ascertainment bias and inadequate access to testing, particularly in low-income and middle-income countries. Advances in detection include improved estimation of glomerular filtration rate (GFR) using cystatin C and the recognition of albuminuria as a key marker for screening and risk stratification. Kidney biopsy is improving diagnostic accuracy and prognostic prediction, and multiomics approaches are advancing our understanding of disease mechanisms and hold promise for precision medicine.
Source: [Series] Advances in the diagnosis and detection of chronic kidney disease